# Iqbal Mufti

> Iqbal Mufti is a Series A investor at SR One (Basel) backing Medical and Life Science. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [SR One](https://shizune.co/investors/profile/sr-one)
- Location: Basel, Switzerland
- Total investments: 3
- Last investment: May 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/iqbal-mufti-9080913/?originalSubdomain=ch

Iqbal Mufti is a Series A investor at SR One in Basel focused on Medical and Life Science. Iqbal Mufti

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Life Science | 1 | 33% |
| Biotechnology | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $200M | Series A | Jan 10, 2025 |  |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. |  |  |  |  |

3 of 3 investments shown.

## Co-investors
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 3 deals together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 3 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [Pivotal bioVenture Partners](https://shizune.co/investors/profile/pivotal-bioventure-partners) — VC Fund, 3 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 3 deals together
- [Quan Capital](https://shizune.co/investors/profile/quan-capital) — VC Fund, 3 deals together

## About SR One

VC Fund · Cambridge, United States

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.

5 contacts available at SR One.

| Name | Title | Profile |
| --- | --- | --- |
| Jill Carroll | Partner | https://shizune.co/investors/profile/jill-carroll |
| Simeon George | Chief Executive Officer | https://shizune.co/investors/profile/simeon-j-george |
| Christopher Y. Chai | Venture Partner | https://shizune.co/investors/profile/christopher-y-chai |
| Iqbal Mufti | Partner | https://shizune.co/investors/profile/iqbal-mufti-e58a |
| Jens Eckstein | President | https://shizune.co/investors/profile/jens-eckstein |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Iqbal Mufti invest in?

Iqbal Mufti invests primarily in Medical, Life Science and Biotechnology startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Iqbal Mufti last invest?

The most recent investment recorded for Iqbal Mufti closed in May 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co